Nautilus Biotechnolgy's market cap is currently ―. The company's EPS TTM is $-0.51; its P/E ratio is -4.82; Nautilus Biotechnolgy is scheduled to report earnings on April 30, 2024, and the estimated EPS forecast is $-0.16. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	-	$ 48.66M	$ 41.75M	-	$ 98.08M
Gross Profit	-	$ 9.95M	$ 8.65M	-	$ 22.86M
EBIT	$ -17.02M	$ -10.95M	$ -1.95M	-	$ -9.57M
EBITDA	$ -16.11M	$ -7.85M	$ 1.20M	-	$ -6.40M
Net Income Common Stockholders	$ -17.02M	$ -12.54M	$ -4.92M	-	$ -11.08M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 173.42M	$ 8.13M	$ 17.33M	$ 17.36M	$ 15.53M
Total Assets	$ 305.56M	$ 167.68M	$ 140.18M	$ 163.53M	$ 225.09M
Total Debt	$ 34.63M	$ 34.66M	$ 35.96M	$ 49.14M	$ 81.75M
Net Debt	$ -138.79M	$ 26.53M	$ 18.63M	$ 31.77M	$ 66.22M
Total Liabilities	$ 40.21M	$ 120.56M	$ 81.11M	$ 102.23M	$ 142.10M
Stockholders Equity	$ 265.35M	$ 47.12M	$ 59.07M	$ 61.30M	$ 82.99M
Cash Flow	-
Free Cash Flow	$ -14.31M	$ -6.29M	$ 6.96M	-	$ -5.37M
Operating Cash Flow	$ -13.90M	$ -5.57M	$ -2.37M	-	$ -2.18M
Investing Cash Flow	$ -41.06M	$ -724.00K	$ 11.67M	-	$ -3.19M
Financing Cash Flow	$ 253.00K	$ -320.00K	$ -9.52M	-	$ 11.08M

Currency in USD

Nautilus Biotechnolgy Earnings and Revenue History

Income Statement >

Nautilus Biotechnolgy Debt to Assets

Balance Sheet >

Nautilus Biotechnolgy Cash Flow

Cash Flow >

Nautilus Biotechnolgy Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing